LINKÖPING, Sweden, August 28, 2025 – AMRA Medical is gearing up for an informative and productive time at ESC 2025 in beautiful Madrid, Spain! Put on by the European Society of Cardiology, together with the World Congress of Cardiology, the Special Edition ESC 2025 meeting will unite global cardiovascular leaders under the theme “Cardiology Beyond Borders” with a spotlight on “Global Health”. The goals include delivering an exceptional program that dissolves barriers, showcases practice-changing science and cutting-edge innovations, and fosters cross-disciplinary collaboration to reduce the burden of cardiovascular disease worldwide.
Our very own Dr. Jennifer Linge will serve as one of three experts during an important session regarding the effects of GLP-1-based treatments on muscle health in cardiometabolic diseases, titled “Great Debate: do GLP-1 analogues/GLP-1 receptor agonists (GLP-1RAs) worsen muscle loss in cardiometabolic disease?” The goal of the session, as outlined by the organizers, is to ”understand the mechanism and clinical role of GLP-1 receptor agonists in cardiometabolic disease; to assess evidence on the potential impact of GLP-1 RAs on muscle mass and function; to compare expert viewpoints on the benefits and risks of GLP-1 RA therapy; and to identify research gaps to guide future studies on cardiometabolic and muscular health.”
Dr. Linge will be joined by cardiometabolic disease thought leaders Stefan Anker (Charite University Hospital – Berlin, Germany) and Naveed Sattar (University of Glasgow – Glasgow, United Kingdom of Great Britain & Northern Ireland) as speakers for the session, which will be chaired by Signe Torekov (University of Copenhagen – Copenhagen, Denmark) and Frieder Braunschweig (Karolinska University Hospital – Stockholm, Sweden) .
Given the Meeting’s theme centered around global health and as GLP-1-based treatments continue to emerge as the preferred intervention for many of those with metabolic disease worldwide, now more than ever is the time to participate in discussions such as this one. The time is now to ensure that the right questions are being asked when it comes to the safety and efficacy of these popular medicines in various disease populations, such as those in cardiometabolic indications and we are excited to be a part of this important event..
If you’ll be at ESC 2025, make sure to catch AMRA and Dr. Linge in action during the session on August 29th @ 13:45 in Hall 10! As the GLP-1-based drug development landscape continues to unfold at dramatic pace, AMRA is at the forefront of designing effective biomarkers that elucidate insights beyond weight loss, supporting emerging therapies in demonstrating their safety and efficacy across a number of disease areas, including cardiovascular disease. You can learn more about how we’re using our mission to advance metabolic disease research and beyond here, or by reaching out to one of our knowledgeable scientists at info@amramedical.com. Make sure to reach out to us if you’ll be attending ESC 2025 – we would love to see you in Madrid!